key: cord-0924820-kabpfe8j
authors: Kannan, M.; Sathiyarajeswaran, P.; Sasikumar, D.; Geetha, A.; Mohanapriya, M.; Vinod, N.P.; Manickam, P.; Kanakavalli, K.; Parthibhan, P.; Pitchiah Kumar, M.; Kannan, R.; Sivaraman, G.
title: Safety and Efficacy of a Siddha Medicine Fixed Regimen for the treatment of Asymptomatic and Mild COVID-19 patients
date: 2022-05-23
journal: J Ayurveda Integr Med
DOI: 10.1016/j.jaim.2022.100589
sha: 7078cf42fd4003cea4947afbef12ea5e312cf5c2
doc_id: 924820
cord_uid: kabpfe8j

BACKGROUND: The Coronavirus disease 2019 (COVID-19) pandemic caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is a massive threat to public health worldwide. Siddha system of medicine is one of the traditional medicines of South India. The recommended formulations in Siddha Sasthric Medicines- Fixed Regimen (SSM-FiRe) are Amukkura tablets, Kaba Sura Kudineer (KSK) for asymptomatic COVID-19 positive (RT-PCR) patients, and Athimathuram tablets, Adathodai Manappagu syrup, Thippili Rasayanam, Brahmananda Bairavam tablet, and Notchi Kudineer for mild symptomatic patients. The core objective of the trial was to document the efficacy of SSM-FiRe in the prevention of asymptomatic and mild COVID-19 disease progression to the next level of severity, reduce the severity of symptoms and revert to RT-PCR Negative. METHODS: An exploratory, prospective, open-labeled, single-arm, non-randomized trial was designed as per GCP guidelines to assess the efficacy of SSM-FiRe. Sixty RT-PCR positive participants who were asymptomatic or with mild COVID-19 symptoms were recruited for the study at the Siddha COVID Care Centre, Vyasarpadi, Chennai from June to Aug. 2020. Nasal and oropharyngeal swab tests were performed on the 0, 7(th), and 14(th) days. All participants were treated with SSM – FiRe regimen. All the participants were also assessed based on Siddha Yakkkaiyin Ilakkanam, which included Clinical symptoms and vitals. Laboratory investigations such as Haemogram, Liver Function Test, Renal Function Test, HbA1C, Electrolytes, Inflammatory markers, Cardiac profile, Immunoglobulins, and anti-SARS-CoV-2 antibody tests were performed. RESULTS: 83% of COVID-19 patients turned RT-PCR negative on the 7(th) day and in most of the cases, symptoms were reduced within the first 5 days of admission. The RT-PCR cycle threshold (ct) value increased significantly (<0.001) after treatment and all the participants were RT-PCR negative, except one, who was positive even after 14 days. Anti-SARS-CoV-2 antibodies developed significantly (p-value – 0.006). LFT, RFT, CBC, Total proteins, and electrolytes continued to be in the normal range after treatment, indicating the safety of the intervention. CONCLUSION: Asymptomatic and mild COVID-19 disease can be well managed by SSM – FiRe treatment, Further studies could be taken up to strengthen the findings.

The world is now interested to reinstate the ancient practice among the public. Therefore, it is the need of the hour to scientifically validate the herbs and herbal formulations 70 against SARS-CoV-2 (8) . Although several drug trials are ongoing all over the world, there is 71 scope for Traditional Medicine to be tested against COVID- 19 . In classical textbooks of Siddha 72 medicine, epidemics and pandemics termed as Uzhi Noi or Kothari Noi or collectively Kollai 73 Noigal have been explained and their possible treatment (9) . This study is investigating the have shown the highest dock score values of above 11.00 (15) . P4 is the new proactive approach 87 to preventing diseases which has predictive, preventive, personalized, and participatory (16) . The study was an interventional prospective, open-label, single-arm, non-randomized 123 trial, Phase II (Exploratory) study, conducted over three months from June to August 2020.

This study intended to explore the efficacy and safety of SSM-FiRe for asymptomatic (COVID- abdominal pain, vomiting, wheezing, and constipation are less than 1%.

During the treatment period, the majority of the symptoms were reduced within 5 days, 247 almost all the symptoms were reduced within 7 days and 1.7% of the patient had a cough, 248 ageusia, and anosmia. The levels of parameters such as SGOT had some mild abnormality in post treatment 266 which shows liver damage persistent due to COVID-19 which is associated with an increased 

There is no significant difference in HbA1c levels before and after treatment as it was 280 well maintained between 6.56%-6.51%. There was no change in the platelet count in pre and among various age groups, genders, educational qualifications, and residence areas (33) .

The most presented symptoms were malaise, cough, anosmia, muscle pain, headache, As per the Siddha classic (35) , the constitution Aiyam has strong immunity, and the 320 Azhal constitution has moderate immunity when compared with the Vali constitution with poor 321 immunity (36) . The increased laboratory values indicate inflammation despite their

Department of Indian medicine & homeopathy, Chennai

Global Covid-19 Case Fatality Rates-CEBM. URL Httpswww Cebm Netcovid-19global-Covid-19-Case-Fatal-Ratesaccessed

COVID-19) Dashboard Data [Internet]. World Health Organization. World Health Organization

WHO | Pneumonia of unknown cause -China

GitHub -CSSEGISandData/COVID-19: Novel Coronavirus (COVID-19) Cases, provided by JHU CSSE

Drug repurposing approach to fight COVID-19

Dexamethasone in hospitalized patients with COVID-19 preliminary report: Discussions from the respirology and sleep Twitter journal club @respandsleepjc (#rsjc). Can J Respir Crit Care Sleep Med

Herbal immune-boosters: Substantial warriors of pandemic Covid-19 battle

Siddha Formulary of India Part II

Coronavirus spike (S) glycoprotein (2019-ncov) targeted siddha medicines kabasura kudineer and thonthasura kudineer-in silico evidence for corona viral drug

Screening of Adathodai Kudineer a Siddha Concoction and Evaluation of

Binding Affinity of Its Constituents with SARS-CoV-2 Spike Protein and ACE2 Receptor Spike Protein Complex Through Molecular Docking In-Silico Approach

In Silico Computational Screening of Kabasura Kudineer-Official Siddha Formulation and JACOM-Novel Herbal Coded Formulation Against SARS-CoV-2 Spike protein

A personal view on systems medicine and the emergence of proactive P4 medicine: predictive, preventive, personalized and participatory

Good Clinical Practice Guidelines for Ayurveda, Siddha and Unani medicine (GCP-ASU). Ministry of AYUSH, Govt of India; 1-104 p. 18. The Wire. Tamil Nadu Government Distributes Herbal Concoction to

COVID-19 in Siddha Medicine: A Review

Clinical Management Protocol, version 3. Govt. of India

Directorate General of Health Services EMR Division. Final Guidance on Mangaement of Covid cases

In vivo evaluation of withania somnifera-based Indian traditional formulation (Amukkara choornam), against chikungunya virus-induced morbidity and arthralgia

Pharmacognostical Standardization, GC-MS ANALYSIS and in vitro screening of AN OFFICIAL SIDDHA FORMULATION-"NOCHI KUDINEER

Ms)

Liver injury in severe COVID-19 infection: current insights and challenges

Hepatic involvement in COVID-19 patients: Pathology, pathogenesis, and clinical implications

Hepatic Injury in Patients With COVID-19

Single-Cell RNA Expression Profiling of ACE2, the Receptor of SARS-CoV-2

COVID-19: Face masks and human-to-human transmission. Influenza Other Respir Viruses

Knowledge, attitudes, and practices towards COVID-19 among Chinese residents during the rapid rise period of the COVID-19 outbreak: a quick online cross-sectional survey

A Review of Coronavirus Disease-2019 (COVID-19)

Concepts of body constitution in traditional Siddha texts: A literature review

Noi Naadal Noi Muthal Naadal Thirattu Part -I

Analogy of Kaba Suram with COVID-19 Symptoms -A Siddha Literature Review

Lactate dehydrogenase, an independent risk factor of severe COVID-19 patients: a retrospective and observational study

D-dimer as a biomarker for disease severity and mortality in COVID-19 patients: a case control study

Prognostic role of D-dimer for inhospital and 1-year mortality in exacerbations of COPD

The Role of Interleukin-6 in the Pathogenesis, Prognosis and Treatment of Severe COVID-19

C-reactive protein, procalcitonin, D-dimer, and ferritin in severe coronavirus disease-2019: a meta-analysis

A Pharmacological Review of Siddha Classical Preparations for the Management of COVID-19 at TPEC COVID Care Centre

The Relevance of Monoclonal Antibodies in the Treatment of COVID-19. Vaccines

Antiinflammatory effect of Kaba Sura Kudineer (AYUSH approved COVID-19 drug)-A Siddha poly-herbal formulation against lipopolysaccharide induced inflammatory response in RAW-264.7 macrophages cells

Dimer elevation and adverse outcomes

Residual Venous Obstruction, alone and in Combination with D-Dimer, as a Risk Factor for Recurrence after Anticoagulation Withdrawal following a First Idiopathic Deep Vein Thrombosis in the Prolong Study

Elevated levels of D-dimer in patients with COVID-19: prognosis value

What is the role of admission HbA1c in managing COVID -19 patients?

Type-2 diabetes, a co-morbidity in Covid-19: does insulin signaling matter?

nCD64 index as a prognostic biomarker for mortality in acute exacerbation of chronic obstructive pulmonary disease